North China Pharmaceutical, Limited operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares North China Pharmaceutical, Limited with three other
companies in this sector in China:
Chongqing Taiji Industry (Group)
sales of 7.78 billion Chinese Renmimbi [US$1.21 billion]
of which 52%
Sichuan Kelun Pharmaceutical Company Limited
(8.57 billion Chinese Renmimbi [US$1.33 billion]
of which 96%
was Medical and Pharmaceutical Products), and
Livzon Pharmaceutical Group Incorporated
(7.65 billion Chinese Renmimbi [US$1.19 billion]
of which 42%
was Western Medicine).
During the year ended December of 2016, sales at
North China Pharmaceutical, Limited were 8.08 billion Chinese Renmimbi (US$1.25 billion).
increase of 2.3%
versus 2015, when the company's sales were 7.90 billion Chinese Renmimbi.
Despite this increase, sales are still
below the level achieved in 2014, when North China Pharmaceutical, Limited
reported sales of 9.40 billion Chinese Renmimbi.
Sales of Biopharmacy saw an increase
that was more than double the company's growth rate: sales were up
28.7% in 2016, from
237.74 million Chinese Renmimbi to 305.87 million Chinese Renmimbi.
North China Pharmaceutical, Limited also saw significant increases in sales in
Chemical Preparation Medicine (up 10.4% to 3.46 billion Chinese Renmimbi)
Medicine and Other Logistics Trade (up 9.7% to 2.20 billion Chinese Renmimbi)
Not all segments of North China Pharmaceutical, Limited experienced an increase in sales in 2016:
sales of Medical Intermediate fell 34.7% to 170.68 million Chinese Renmimbi.
(However, this segment's sales were only a very small portion of the company's overall sales).
North China Pharmaceutical, Limited also experienced decreases in sales in
Chemical Raw Medicine (down 15.7% to 1.66 billion Chinese Renmimbi)
Other (down 13.1% to 92.89 million Chinese Renmimbi)